Abstract #1907
A NIR830-Bevacizumab-Conjugated Iron Oxide Nanoparticle Probe for Vascular Endothelial Growth Factor (VGEF) Targeted MRI
Run Lin 1,2 , Jing Huang 1 , Liya Wang 1 , Yuancheng Li 1 , Prieto Ventura Veronica E 1 , Kevin Kim 1 , and Hui Mao 1
1
Department of Radiology and Imaging
Sciences, Emory University School of Medicine, Atlanta,
GA, United States,
2
Department
of Radiology, the First Affiliated Hospital of Sun
Yat-Sen University, Guangzhou, Guangdong, China
Vascular endothelial growth factor (VEGF) plays a
pivotal role in the cascade of development and
progression of cancers by promoting angiogenesis.
Targeting this biomarker would be a logical strategy for
imaging based cancer detection and anti-angiogenesis
treatment. Bevacizumab is a recombinant humanized
monoclonal antibody directly against VEGF and is
currently used in clinic for treating various cancers
with VEGF overexpression. In this study, a VEGF targeted
molecular imaging probe was developed by conjugating
near infrared dye (NIR830) labeled bevacizumab to
magnetic iron oxide nanoparticles (IONP) for optical and
magnetic resonance (MR) imaging of cancers
overexpressing VEGF.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
